Search results
Results from the WOW.Com Content Network
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
Trade names: Actimoxi, Alphamox, etc. 21 clinical Plain demo: Drugs.com = AHFS/Drugs.com: Monograph: 23 clinical Input by {} MedlinePlus = MedlinePlus: 25: clinical licence_EU = DailyMedID = licence_US = Licence data
Drug name: drug_name: Name of the drug, medication, or vaccine, including combination drugs. The article title will be used if this is left blank. String: suggested: type: type: Drug type, can be left <blank> (for single chemical), "vaccine", "combo" (combination of drugs), and "mab" (monoclonal antibody) Example combo: String: suggested: IUPAC ...
Formulations and brand names of norethisterone and esters Composition Dose Brand names Use NET only: Low (e.g., 0.35 mg) Multiple [a] Progestogen-only oral contraceptive: NET or NETA only: High (e.g., 5 mg, 10 mg) Multiple [b] Gynecological disorders and other uses NETE only: Injection (e.g., 200 mg) Multiple [c] Progestogen-only injectable ...
This is the template test cases page for the sandbox of Template:Infobox drug to update the examples. If there are many examples of a complicated template, later ones may break due to limits in MediaWiki; see the HTML comment "NewPP limit report" in the rendered page. You can also use Special:ExpandTemplates to examine the results of template uses. You can test how this page looks in the ...
The template does not at the current time include summary information about the drug class itself. Instead, it contains a consistent interface to other sources that provide information about the drug class. Don't worry about trying to fill in all the fields – even if you can only get one or two, that still can be useful.
Schedule 13G is an alternative SEC filing for the Schedule 13D which can be filed in lieu of Schedule 13D by anyone who acquires more than 5% ownership of a Section 13 security and qualifies for one of the exemptions available to the Schedule 13D filing requirement.
Schedule 13D is an SEC filing that must be submitted to the US Securities and Exchange Commission within 10 days by anyone who acquires beneficial ownership of more than 5% of any class of publicly traded securities in a public company. A filer must promptly update the Schedule 13D filing to reflect any material change in the facts disclosed ...